Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > I'm In
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by porksnifferon Sep 02, 2021 11:31am
82 Views
Post# 33800734

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:I'm In

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:I'm In
Snowballgrowth wrote:
Chianchin wrote: $50 million cashflow? Investors could care less about it. GUD to be worth $5 needs to make about $65 million poifit ".$.50 a share. GILD trades at a PE of 10 because HAS NO GROWT just like GUD stock in mud faillures 


Did you forget the cash and the investments in funds + current growth in your estimate of the intriinsic value ?



The 'cash and investments' are illiquid and market always values this as exactly...zero, rookie.

The shareholder base continues to rollover. Top holders have been leaving this 5 year underperforming turd for a year now. The value guys buying today will also get trapped just like many on this forum. Meir warned you. You have been absolutely brainwashed here by Mugs and it will cost you a fortune. Keep praising the job management is doing.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities